Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Argatroban

Argatroban

Parenteral direct thrombin inhibitor

HITIVICUAdult

Indication

Suspected/confirmed HIT thrombosis β€’ Bridging in HIT β€’ Selected PCI

At a glance

INDICATIONS (CORE USE)

**HIT** management and PCI in HIT when protocol mandates; **hepatic** clearance β€” aPTT monitoring.

ADULT DOSE (STANDARD)

IV infusion **mcg/kg/min** β€” titrate **aPTT** 1.5–3Γ— baseline per protocol

MAX DOSE

Protocol max infusion rate

Route

IV

PEDIATRIC DOSE

Limited pediatric protocols β€” specialist

Do not miss

Must-not-miss safety points

Major warning

- **Bleeding** β€” especially with other anticoagulants - **Hepatic impairment** β†’ major dose reduction - Transition overlap to warfarin β€” argatroban prolongs INR (interpretation nuance)

Indications

USE IF: HIT when non-heparin anticoagulation required. AVOID IF: Uncorrected severe bleeding, uncontrolled HTN per label context.

Primary

  • Prophylaxis/treatment of thrombosis in HIT
  • PCI with HIT (specialized centers)

Dosing

STANDARD (ADULT PO)

Start 2 mcg/kg/min IV (adjust hepatic impairment) β€” titrate aPTT

ADULT DOSE

Hepatic impairment β†’ lower starting rate per label; ICU monitoring.

PEDIATRIC DOSE

PICU protocol only

MAX DOSE

Per institutional cap

Practical Note

INR rises on combined warfarin+argatroban β€” follow specific overlap stopping rules.

Warnings

Clinical warnings

  • Combined warfarin therapy INR interpretation
  • hepatic failure accumulation

Adverse effects

  • Bleeding
  • hypotension
  • fever

Contraindications

  • **Active pathological / major bleeding** β€” stabilize/reverse per protocol before routine (re)start unless embedded in explicit reversal plan
  • **Upcoming invasive procedure** β€” **do not continue blindly**; document **hold/bridge/switch** with anesthesia/surgery when applicable
  • Major bleeding
  • hypersensitivity

Drug interactions

  • **NSAID, antiplatelet, or SSRI added** β†’ **bleeding risk ↑** β†’ **reassess stack** and procedure timing
  • **Renal decline** on renally cleared agent β†’ **dose/hold** per CrCl + pharmacy
  • Other anticoagulants
  • thrombolytics
  • GP IIb/IIIa

Special populations

Pediatrics

Limited pediatric protocols β€” specialist

Pregnancy

Limited β€” specialist; risk/benefit in HIT emergency

Lactation

See lactation references and product labeling.

Renal impairment

Hepatic clearance dominant β€” renal failure less dose issue than bivalirudin **CrCl scaffold (FMBM β€” titrate to FDA/SFDA label + pharmacy / anticoagulation clinic):** - **CrCl β‰₯50** β†’ **Argatroban:** hepatic clearance dominant β†’ Child-Pugh adjustment; **Bivalirudin:** renal clearance significant - **CrCl 10–50** β†’ **Bivalirudin** β†’ reduce infusion rate per PCI label; monitor ACT - **CrCl <10** β†’ **Bivalirudin** β†’ further dose reduction / specialist PCI protocol; **Argatroban** if hepatic failure β†’ major dose reduction

Hepatic impairment

**Child-Pugh** impairment β†’ reduce starting dose and monitor closely

Elderly

Hepatic function and bleed risk

Administration

IV infusion dedicated line; ICU/cath lab

Monitoring

  • Monitor: - **What to check + when:** **aPTT** (argatroban) or **ACT** (bivalirudin PCI) per protocol β€” titrate on scheduled lab intervals (ICU/cath lab) - **Escalation β€” lab off target, no bleed:** Titrate infusion per protocol - **Escalation β€” bleeding:** **Stop infusion** β€” offset short but **organ failure prolongs** - **Escalation β€” HIT β†’ warfarin overlap:** **Institutional INR rules** β€” premature stop risks thrombosis - **Starting warfarin for acute VTE** β†’ **parenteral overlap** when indicated β€” **do not stop parenteral prematurely** per guideline - **Low-risk AF elective surgery** β†’ **avoid routine bridging** β€” use thromboembolic risk stratification - aPTT per protocol until stable - hemoglobin if bleeding
  • Recheck: - **Procedure or neuraxial in 48–72h** β†’ **reassess anticoagulant plan** β€” DOAC hold windows **β‰ ** warfarin; document last dose time - **Interacting drug added or stopped** β†’ **recheck INR (warfarin) or reassess bleed risk / renal (DOAC)** within **48–72h** - If targets not met after reassessment of dose, organ function, and interactions β†’ escalate per protocol (DO NOT continue blindly)
  • Hold if:
    - **Bleeding, unexplained Hb drop, thunderclap headache, or focal neuro signs** β†’ **hold** anticoagulant + escalate per bleed protocol

Overdose / toxicity

Clinical Picture

β€’ **No bleed:** Supratherapeutic **aPTT** (argatroban) or **ACT** (bivalirudin) β†’ titrate infusion β€’ **Minor bleed:** Reduce rate + mechanical hemostasis β€’ **Major bleed:** Stop infusion β†’ supportive; **PCC** refractory-only per protocol + **ICU**

Immediate Actions

β€’ **No bleed:** Lab-guided rate ↓/brief stop β†’ retitrate β€’ **Minor bleed:** Hold/↓ rate + local control β€’ **Major bleed:** Stop infusion β†’ resuscitation β†’ source control; offset short but **organ failure prolongs**

Antidote

**No specific antidote** β€” stop drug/supportive care; **major bleed** β†’ institutional reversal pathway; anaphylaxis β†’ **epinephrine** per ACLS

Decontamination

β€’ **N/A**

Escalation

β€’ **Major:** **ICU** + hematology β€’ **HIT β†’ oral overlap:** Follow **institutional INR transition** rules

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

**HIT drug** β€” not routine VTE first-line. β†’ **Hepatic** dose. β†’ **aPTT** not anti-Xa.

Clinical pearls

Bivalirudin is renal; argatroban is hepatic β€” pick the right organ failure drug. *Anticoagulation (all agents):* **A/B/C bleed tiers** β€” no bleed (hold/adjust) vs minor (hold/protocol) vs major (reversal + ICU/heme). **Warfarin:** high INR without bleed **β‰ ** major-bleed pathway; **PCC + IV K** for life-threatening bleed. **Bridging:** warfarin **slow on/off**; **parenteral overlap** when indicated for acute VTE; **no routine bridge** low-risk AF; **DOAC↔warfarin** table-specific. **Neuraxial:** explicit **last-dose β†’ procedure** documentation. Never extend therapy without indication review.

Anticoagulant safety

  • aPTT titration
  • Hepatic dose
  • Warfarin overlap

Pharmacokinetics

Hepatic metabolism; short half-life after infusion stop.

Mechanism of action

Selective thrombin inhibitor (IV).

Common brand names

Saudi Arabia

Argatroban

Global

(placeholder β€” verify local prefilled syringe / vial)

Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

  • Reversal agents (PCC, andexanet, idarucizumab) availability and dosing vary by hospital β€” follow local protocol.
  • Perioperative interruption and bridging are **indication-specific** β€” do not copy warfarin rules onto DOACs blindly.
  • Switching between anticoagulants requires manufacturer tables + pharmacy to avoid under- or over-anticoagulation.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • CHEST / ACCP antithrombotic guidance (indication-specific)
  • ESC / AHA stroke and anticoagulation guidelines where applicable
  • ASH β€” HIT and VTE resources
  • FDA / SFDA product labeling
  • Institutional anticoagulation service / formulary
  • CHEST / ACCP antithrombotic guidance (indication-specific)
  • ESC / AHA stroke and anticoagulation guidelines where applicable
  • ASH β€” HIT and VTE resources
  • FDA / SFDA product labeling
  • Institutional anticoagulation service / formulary

Do not miss

  • Document indication, target intensity, and planned duration in the chart
  • Reassess renal/hepatic function after AKI, dehydration, or new interacting medications
  • **Lab target:** Argatroban **aPTT** vs bivalirudin **ACT** β€” do not interchange monitoring.
  • **Organ failure:** Argatroban **hepatic**; bivalirudin **renal** β€” dose adjust or switch agent per protocol.
  • **Transition:** HIT or PCI overlap to oral agent β†’ **pharmacy table** β€” premature stop risks thrombosis.
  • Warfarin overlap β€” **INR cooked** by argatroban β€” use institutional stopping rule.
  • **Bridging & transitions (factory scaffold):**
  • **Warfarin** has **delayed onset/offset** β€” do not expect immediate effect or rapid washout like DOACs.
  • **Acute thrombosis** may require **parenteral overlap** when starting/overlapping warfarin or per label β€” **indication-specific**.
  • **Low-risk AF peri-procedure:** **do NOT routinely bridge** β€” stratify thromboembolic risk per guideline/CHEST-style tables.
  • **DOAC ↔ warfarin** switches are **indication- and table-specific** β€” pharmacy + label (valve, APS, renal).
  • **Neuraxial / high-bleed procedure:** document **last dose**, **ASRA/institutional** windows, **restart** only when hemostasis secure.
  • aPTT titration
  • Hepatic dose
  • Warfarin overlap